Pipeline Overview

Our Approach Has Created an Innovative Pipeline
in Targeted Radiopharmaceuticals

ProgramIndicationDiscoveryLead OptimizationDevelopment CandidateClinical imaging, IND enablingClinical Trials (Phase 1-3)
RYZ101
(225Ac DOTATATE)

 
RYZ101
(225Ac DOTATATE)

 
Program A
(Novel Peptide)
Multiple Solid Tumors

 
Program B
(Novel Small Molecule)
Multiple Solid Tumors

 
Program C
(Novel Peptide)
Liver Cancer

 
Program D
(Novel Peptide)
Multiple Solid Tumors

 
Program E
(Novel Peptide)
Multiple Solid Tumors

 
Other Programs
(Peptide/Small Molecules)
Multiple Solid Tumors

 
DrugIndicationStage
RYZ101
(225Ac DOTATATE)
Neuroendocrine TumorsClinical Trials (Phase 1-3)
RYZ101
(225Ac DOTATATE)
Small Cell Lung CancerClinical Trials (Phase 1-3)
Program A
(Novel Peptide)
Multiple Solid TumorsDevelopment Candidate
Program B
(Novel Small Molecule)
Multiple Solid TumorsDevelopment Candidate
Program C
(Novel Peptide)
Liver CancerDevelopment Candidate
Program D
(Novel Peptide)
Multiple Solid TumorsLead Optimization
Program E
(Novel Peptide)
Multiple Solid TumorsDiscovery
Other Programs
(Peptide/Small Molecules)
Multiple Solid TumorsDiscovery